| Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 11768722 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The object of this study is to evaluate the long-term effects of olmesartan on hypertension and the renin-angiotensin-aldosterone system in hypertensive patients. This study evaluated 26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure > or = 160 mmHg and/or a diastolic blood pressure > or = 95 mmHg. Oral doses of 5 to 40 mg olmesartan were administered once daily. Blood pressure and renin-angiotensin-aldosterone parameters (plasma renin activity and plasma angiotensin I, II, and aldosterone concentrations) were evaluated at 12-16 weeks, 6 months, and 1 year after the start of olmesartan administration. Systolic and diastolic blood pressures were significantly decreased following the administration of olmesartan. The observed decreases in systolic and diastolic blood pressures after 1 year of treatment were 28.8+/-2.1 mmHg and 15.8+/-1.3 mmHg, respectively. No change was observed in the pulse rate. The plasma renin activity increased significantly from a baseline premedication mean of 1.26+/-0.31 ng/ml/h to a mean of 2.58+/-0.74 ng/ml/h and 2.87+/-0.72 ng/ml/h after 6 months and 1 year of treatment, respectively. Angiotensin II levels decreased significantly from a baseline of 20.4+/-3.2 pg/ml to a mean of 8.6+/-2.1 pg/ml and 6.8+/-1.8 pg/ml after 6 months and 1 year of treatment, respectively. The plasma aldosterone level also decreased significantly after 6 months of treatment. In hypertensive patients, the long-term administration of olmesartan, a novel AT1 receptor antagonist, decreased both blood pressure and plasma angiotensin II levels. |
| | |
Authors:
|
S Ichikawa; Y Takayama |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Hypertension research : official journal of the Japanese Society of Hypertension Volume: 24 ISSN: 0916-9636 ISO Abbreviation: Hypertens. Res. Publication Date: 2001 Nov |
Date Detail:
|
Created Date: 2001-12-21 Completed Date: 2002-05-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9307690 Medline TA: Hypertens Res Country: Japan |
Other Details:
|
Languages: eng Pagination: 641-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Cardiovascular Hospital of Central Japan, Seta-gun, Gunma. ichikawa@ccj.or.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aldosterone / blood* Angiotensin I / blood Angiotensin II / blood Antihypertensive Agents / therapeutic use* Blood Pressure / drug effects* Female Humans Hypertension / drug therapy*, physiopathology* Imidazoles / adverse effects, therapeutic use* Male Middle Aged Pulse Receptors, Angiotensin / antagonists & inhibitors* Renin / blood Renin-Angiotensin System / drug effects* Respiration Disorders / chemically induced Tetrazoles / adverse effects, therapeutic use* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Imidazoles; 0/Receptors, Angiotensin; 0/Tetrazoles; 11128-99-7/Angiotensin II; 144689-24-7/olmesartan medoxomil; 52-39-1/Aldosterone; 9041-90-1/Angiotensin I; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An association study of five genetic loci and left ventricular hypertrophy amongst Gulf Arabs.
Next Document: Effects of a community-based lifestyle-modification program on cardiovascular risk factors in middle...